Latest news

Novartis bets $1.4B on anti-inflammatory heart drug in Tourmaline buyout

Novartis bets $1.4B on anti-inflammatory heart drug in Tourmaline buyout

Eduardo Longoria
Daily Snap - 9. September 2025

Daily Snap - 9. September 2025

Joachim Eeckhout
NRG Therapeutics raises $67M to target Parkinson’s and ALS through mitochondria

NRG Therapeutics raises $67M to target Parkinson’s and ALS through mitochondria

Eduardo Longoria
BioNTech, BMS aim to upend lung cancer treatment with new bispecific drug

BioNTech, BMS aim to upend lung cancer treatment with new bispecific drug

Eduardo Longoria
Daily Snap - 5. September 2025

Daily Snap - 5. September 2025

Joachim Eeckhout
Sanofi’s eczema drug hits targets but disappoints investors

Sanofi’s eczema drug hits targets but disappoints investors

Eduardo Longoria
Enveda secures another $150M to fast-track nature-based drug pipeline

Enveda secures another $150M to fast-track nature-based drug pipeline

Eduardo Longoria
Daily Snap - 4. September 2025

Daily Snap - 4. September 2025

Joachim Eeckhout
FDA proposes rare disease drug pathway but analysts question its real impact

FDA proposes rare disease drug pathway but analysts question its real impact

Eduardo Longoria
Novartis doubles down on RNAi heart drugs with $160M Argo deal

Novartis doubles down on RNAi heart drugs with $160M Argo deal

Eduardo Longoria
Daily Snap - 3. September 2025

Daily Snap - 3. September 2025

Joachim Eeckhout
Novartis bets $2.2B on Arrowhead’s RNA brain drug to crack Parkinson’s code

Novartis bets $2.2B on Arrowhead’s RNA brain drug to crack Parkinson’s code

Eduardo Longoria
FirstBack
1415161718192021
Next Last